Name: Cagrilintide
Brand: Amino Club
SKU: Cagrilintide - 10MG
Availability: InStock
Rating: 5.0 (1 reviews)

Cagrilintide | 99%+ Pure Peptide | Amino Club | Amino Club

Frequently Asked Questions

Common questions about cagrilintide research

Cagrilintide is a long-acting synthetic analog of amylin, a hormone naturally co-secreted with insulin from pancreatic beta cells. Unlike GLP-1 receptor agonists such as semaglutide (Ozempic/Wegovy), cagrilintide works through the amylin and calcitonin receptor pathways. It targets both homeostatic (hunger/fullness) and hedonic (food reward/craving) appetite centers in the brain, providing a complementary mechanism to GLP-1 drugs.

In a Phase 2 trial, cagrilintide monotherapy at 4.5mg achieved 10.8% weight loss over 26 weeks. In the Phase 3 REDEFINE 1 trial, cagrilintide alone (2.4mg) produced 11.5% weight loss at 68 weeks. When combined with semaglutide (as CagriSema), weight loss reached 20.4% at 68 weeks — a 5.5% improvement over semaglutide alone (14.9%). Over 90% of CagriSema participants achieved clinically meaningful weight loss (≥5%).

CagriSema is a fixed-dose combination of cagrilintide (an amylin analog) and semaglutide (a GLP-1 receptor agonist) being developed by Novo Nordisk. It combines two complementary appetite regulation pathways in a single once-weekly injection. CagriSema was submitted to the FDA for weight management in December 2025 based on the REDEFINE 1 and REDEFINE 2 Phase 3 trial results.

The most common side effects are gastrointestinal: nausea, constipation, diarrhea, and vomiting. These are consistent with other amylin- and GLP-1-based therapies, were mostly mild-to-moderate in severity, and typically diminished over time. In REDEFINE 1, the discontinuation rate due to adverse events was 5.9% for CagriSema compared to 2.6% for placebo. Cagrilintide monotherapy had lower GI event rates than the combination.

Cagrilintide is administered as a once-weekly subcutaneous injection. Its long half-life of approximately 7-8 days (159-195 hours) enables this convenient dosing schedule. In clinical trials, treatment was started at a low dose (0.25mg) and gradually escalated over several weeks to the target dose of 2.4mg to minimize gastrointestinal side effects.

No, cagrilintide is not yet approved by any regulatory authority. It is an investigational compound currently in Phase 3 clinical trials. Novo Nordisk submitted CagriSema (cagrilintide + semaglutide combination) to the FDA for weight management in December 2025. The company is also conducting additional trials (REIMAGINE program) in type 2 diabetes before approaching regulators for that indication.

As a research peptide in lyophilized form, cagrilintide should be stored at -20°C for long-term storage. Once reconstituted, it should be kept refrigerated at 2-8°C and used promptly. It should be protected from light and repeated freeze-thaw cycles should be avoided to maintain stability.

Cagrilintide

The Amylin Pathway

Amylin Receptors

Calcitonin Receptor

A Different Approach to Appetite

Homeostatic + Hedonic Regulation

Weight Loss by Treatment Group (REDEFINE 1, 68 weeks)

Key Milestones Reached in REDEFINE 1

CagriSema vs Other Weight Loss Approaches

Cagrilintide Monotherapy (Phase 2)

Dual Appetite Pathway Modulation

Glycemic Control in T2D

Cardiometabolic Markers

Nausea

Constipation

Diarrhea

Vomiting

Injection site reaction

How Many Stopped Due to Side Effects

Who Could Not Participate in Trials

💡Researcher Notes

What Is Cagrilintide?

Stability Information

Where It Stands

What is cagrilintide and how is it different from GLP-1 drugs?

What has research shown about cagrilintide for weight loss?

What is CagriSema?

What side effects have been reported in clinical trials?

How is cagrilintide administered?

Is cagrilintide FDA approved?

How should cagrilintide be stored?

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial

Structural and dynamic features of cagrilintide binding to calcitonin-family receptors

Development of Cagrilintide, a Long-Acting Amylin Analogue

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity

Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3

Cagrilintide — CID 171397054

CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial

REDEFINE 1 — A Research Study to See How Well CagriSema Works in People Living With Overweight or Obesity

⚠️Important Research Notice

All the research peptides you need, with the peace of mind and research community at your fingertips.

Stay Updated with Amino Club

Researcher Notes